Predictive Value of Angiopoietin-like Protein 8 in Metabolic Dysfunction-associated Fatty Liver Disease and Its Progression: A Case-control Study

Overview

Journal World J Diabetes

Publisher Baishideng Publishing Group

Specialty Endocrinology

Date 2024 Apr 9

PMID 38591072

Authors

Lu-Lu Gan

Can Xia

Xuan Zhu

Yue Gao

Wen-Chang Wu

Qi Li

Ling Li

Zhe Dai

Yi-Min Yan

Affiliations

Soon will be listed here.

Abstract

Background: The prevalence of metabolic dysfunction-associated fatty liver disease (MAFLD) is rapidly increasing, currently affecting approximately 25% of the global population. Liver fibrosis represents a crucial stage in the development of MAFLD, with advanced liver fibrosis elevating the risks of cirrhosis and hepatocellular carcinoma. Simple serum markers are less effective in diagnosing liver fibrosis compared to more complex markers. However, imaging techniques like transient elastography face limitations in clinical application due to equipment and technical constraints. Consequently, it is imperative to identify a straightforward yet effective method for assessing MAFLD-associated liver fibrosis.

Aim: To investigate the predictive value of angiopoietin-like protein 8 (ANGPTL8) in MAFLD and its progression.

Methods: We analyzed 160 patients who underwent abdominal ultrasonography in the Endocrinology Department, Xiaogan Central Hospital affiliated to Wuhan University of Science and Technology, during September 2021-July 2022. Using abdominal ultrasonography and MAFLD diagnostic criteria, among the 160 patients, 80 patients (50%) were diagnosed with MAFLD. The MAFLD group was divided into the liver fibrosis group ( = 23) and non-liver fibrosis group ( = 57) by using a cut-off fibrosis-4 index ≥ 1.45. Logistical regression was used to analyze the risk of MAFLD and the risk factors for its progression. Receiver operating characteristic curves were used to evaluate the predictive value of serum ANGPTL8 in MAFLD and its progression.

Results: Compared with non-MAFLD patients, MAFLD patients had higher serum ANGPTL8 and triglyceride-glucose (TyG) index (both < 0.05). Serum ANGPTL8 ( = 0.576, < 0.001) and TyG index ( = 0.473, < 0.001) were positively correlated with MAFLD. Serum ANGPTL8 was a risk factor for MAFLD [odds ratio (OR): 1.123, 95% confidence interval (CI): 1.066-1.184, < 0.001). Serum ANGPTL8 and ANGPTL8 + TyG index predicted MAFLD [area under the curve (AUC): 0.832 and 0.886, respectively; both < 0.05]. Compared with MAFLD patients without fibrosis, those with fibrosis had higher serum ANGPTL8 and TyG index (both < 0.05), and both parameters were positively correlated with MAFLD-associated fibrosis. Elevated serum ANGPTL8 (OR: 1.093, 95%CI: 1.044-1.144, < 0.001) and TyG index (OR: 2.383, 95%CI: 1.199-4.736, < 0.013) were risk factors for MAFLD-associated fibrosis. Serum ANGPTL8 and ANGPTL8 + TyG index predicted MAFLD-associated fibrosis (AUC: 0.812 and 0.835, respectively; both < 0.05).

Conclusion: The serum levels of ANGPTL8 are elevated and positively correlated with MAFLD. They can serve as predictors for the risk of MAFLD and liver fibrosis, with the ANGPTL8 + TyG index potentially exhibiting even higher predictive value.

References

Yang S, Jiao X, Huo X, Zhu M, Wang Y, Fang X . Association between circulating full-length angiopoietin-like protein 8 and non-high-density lipoprotein cholesterol levels in Chinese non-diabetic individuals: a cross-sectional study. Lipids Health Dis. 2018; 17(1):161. PMC: 6052512. DOI: 10.1186/s12944-018-0802-9. View

Zhang P, Dong X, Zhang W, Wang S, Chen C, Tang J . Metabolic-associated fatty liver disease and the risk of cardiovascular disease. Clin Res Hepatol Gastroenterol. 2022; 47(1):102063. DOI: 10.1016/j.clinre.2022.102063. View

Yin Y, Ding X, Peng L, Hou Y, Ling Y, Gu M . Increased Serum ANGPTL8 Concentrations in Patients with Prediabetes and Type 2 Diabetes. J Diabetes Res. 2017; 2017:8293207. PMC: 5610791. DOI: 10.1155/2017/8293207. View

Vallet-Pichard A, Mallet V, Nalpas B, Verkarre V, Nalpas A, Dhalluin-Venier V . FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology. 2007; 46(1):32-6. DOI: 10.1002/hep.21669. View

Hong B, Liu J, Zheng J, Ke W, Huang Z, Wan X . Angiopoietin-like protein 8/betatrophin correlates with hepatocellular lipid content independent of insulin resistance in non-alcoholic fatty liver disease patients. J Diabetes Investig. 2017; 9(4):952-958. PMC: 6031491. DOI: 10.1111/jdi.12792. View

Zhao Z, Deng X, Jia J, Zhao L, Wang C, Cai Z . Angiopoietin-like protein 8 (betatrophin) inhibits hepatic gluconeogenesis through PI3K/Akt signaling pathway in diabetic mice. Metabolism. 2021; 126:154921. DOI: 10.1016/j.metabol.2021.154921. View

Zhang R, Zhang K . An updated ANGPTL3-4-8 model as a mechanism of triglyceride partitioning between fat and oxidative tissues. Prog Lipid Res. 2021; 85:101140. PMC: 8760165. DOI: 10.1016/j.plipres.2021.101140. View

Zhang Z, Yuan Y, Hu L, Tang J, Meng Z, Dai L . ANGPTL8 accelerates liver fibrosis mediated by HFD-induced inflammatory activity via LILRB2/ERK signaling pathways. J Adv Res. 2022; 47:41-56. PMC: 10173191. DOI: 10.1016/j.jare.2022.08.006. View

Lee Y, Lee S, Lee C, Kim S, Song Y, Yoon M . Association between betatrophin/ANGPTL8 and non-alcoholic fatty liver disease: animal and human studies. Sci Rep. 2016; 6:24013. PMC: 4820743. DOI: 10.1038/srep24013. View

10.

Vatner D, Goedeke L, Camporez J, Lyu K, Nasiri A, Zhang D . Angptl8 antisense oligonucleotide improves adipose lipid metabolism and prevents diet-induced NAFLD and hepatic insulin resistance in rodents. Diabetologia. 2018; 61(6):1435-1446. PMC: 5940564. DOI: 10.1007/s00125-018-4579-1. View

11.

Ye J, Qin Y, Wang D, Yang L, Yuan G . The Relationship between Circulating ANGPTL8/Betatrophin Concentrations and Adult Obesity: A Meta-Analysis. Dis Markers. 2019; 2019:5096860. PMC: 6854917. DOI: 10.1155/2019/5096860. View

12.

Ji J, Wu L, Wei J, Wu J, Guo C . The Gut Microbiome and Ferroptosis in MAFLD. J Clin Transl Hepatol. 2022; 11(1):174-187. PMC: 9647110. DOI: 10.14218/JCTH.2022.00136. View

13.

Cengiz M, Ozenirler S, Kocabiyik M . Serum β-trophin level as a new marker for noninvasive assessment of nonalcoholic fatty liver disease and liver fibrosis. Eur J Gastroenterol Hepatol. 2015; 28(1):57-63. DOI: 10.1097/MEG.0000000000000502. View

14.

Wang H, Lai Y, Han C, Liu A, Fan C, Wang H . The Effects of Serum ANGPTL8/betatrophin on the Risk of Developing the Metabolic Syndrome - A Prospective Study. Sci Rep. 2016; 6:28431. PMC: 4921843. DOI: 10.1038/srep28431. View

15.

Amzolini A, Fortofoiu M, Barau Abu-Alhija A, Vladu I, Clenciu D, Mitrea A . Triglyceride and glucose index: a useful tool for non-alcoholic liver disease assessed by liver biopsy in patients with metabolic syndrome?. Rom J Morphol Embryol. 2022; 62(2):475-480. PMC: 8848285. DOI: 10.47162/RJME.62.2.13. View

16.

Xie Z, Li H, Wang B, Yang Z, Zhang Z, Tan W . Trends in prevalence and all-cause mortality of metabolic dysfunction-associated fatty liver disease among adults in the past three decades: Results from the NHANES study. Eur J Intern Med. 2023; 110:62-70. DOI: 10.1016/j.ejim.2023.01.029. View

17.

Eslam M, Sanyal A, George J . MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology. 2020; 158(7):1999-2014.e1. DOI: 10.1053/j.gastro.2019.11.312. View

18.

. Consensus on the diagnosis and treatment of hepatic fibrosis (2019). J Dig Dis. 2020; 21(3):127-138. DOI: 10.1111/1751-2980.12854. View

19.

Abu-Farha M, Ghosh A, Al-Khairi I, Murthy Madiraju S, Abubaker J, Prentki M . The multi-faces of Angptl8 in health and disease: Novel functions beyond lipoprotein lipase modulation. Prog Lipid Res. 2020; 80:101067. DOI: 10.1016/j.plipres.2020.101067. View

20.

Lee J, Vali Y, Boursier J, Spijker R, Anstee Q, Bossuyt P . Prognostic accuracy of FIB-4, NAFLD fibrosis score and APRI for NAFLD-related events: A systematic review. Liver Int. 2020; 41(2):261-270. PMC: 7898346. DOI: 10.1111/liv.14669. View